Ever wish you were a fly on the wall in another laboratory? Well, a new journal website offers the industry opportunities to do just that—to see through video how other scientists carry out particular experiments and processes. Read more »
Archive for the 'Information Technology' Category
We love social media here at PharmTech.com, but many pharma companies have been wary about how to make the most of these new communication platforms—and understandably so given that last year Novartis received an FDA warning letter about a Facebook widgit on its website.
One pharma company that does seem to love social media though is Germany-based Merck KGaA—so much so that the company was prepared to go to court when its Facebook page was recently taken over by US rival Merck & Co. Read more »
The pharma industry has been scratching its head for some time about how best to exploit social media and efforts in this area have been tentative with uncertainty over regulations. Pharmaceutical spammers, on the other hand, have little reason to hold back. Already, spammers are taking advantage of Twitter to promote cheap pharmaceutical products such as Viagra and Levitra. Indeed, a recent study by the University of Akron in the US explained that Twitter “presents a new forum for spammers to facilitate illegal pharmaceutical scams”. Read more »
The other day I was editing an interesting piece about e-prescribing in Europe. A lot of processes in both healthcare and the pharma industry, as well as in every other aspect of our lives, are moving to electronic systems and, of course, such systems offer many benefits. Being sceptical, however, I turned to my colleague and asked, “what happens when the system goes wrong?” Because, let’s face it, all electronic systems seem to suffer serious issues at some point. Read more »
When natural disasters such as Hurricane Irene strike, obtaining food, water, and supplies tend to be at the top of at-risk residents’ minds. Having necessary medication—and enough of it—is also crucial. Even before Irene hit the US coast last week, PhRMA issued an alert to the public about documenting existing prescription medications with the RxResponse online medication card tool. Read more »
The online sale of pharmaceutical products is a big headache for regulators. The Internet is the counterfeiter’s dream market stall, and virtually begs to be abused. Some surveys suggest that more than 60% of drugs purchased online are fake. But governments and regulators are fighting back. In July, the EMA welcomed a new directive on falsified medicines that had a strong focus on the sale of illegal medicinal products on the Internet—somewhat obscurely referred to as “sale at a distance to the public”—and the European Commission was charged with creating a cryptographic logo to identify legal sites.
Stock prices have fluctuated wildly in response to factors such as persistently high unemployment, impending cuts in federal spending, and the downgrade of America’s credit rating. The already conservative pharmaceutical industry is hunkering down and socking away cash to be safe. Since January, Merck has saved $1 billion in cash, and Johnson & Johnson has saved $3 billion. The savings have come at the expense of R&D budgets, making observers wonder where the new drugs will come from.
As a geek, I’m interested in anything related to computers so throughout June I’ve been following the reports of hack attacks on a number of big names including Sony, Nintendo, the Brazilian government and the US Central Intelligence Agency (CIA). Earlier this week, the news website Information Age also reported that Bayer’s Italian website experienced “illegal interference” by hackers last weekend. At the beginning of June, the UK’s National Health Service (NHS) was also attacked by the hacking group Lulz Security (commonly known as LulzSec). In an email sent on 9 June, LulzSec claimed to have obtained admin passwords from the NHS website. The email also added: “We mean you no harm and only want to help you fix your tech issues.” Read more »
Recently, I spoke to R. Arun Kumar about the wider applications of cloud computing. Arun Kumar is Vice President and Head of the Global Life Sciences Business Unit at Infosys, an IT, business consulting and outsourcing services provider. Read more »
So, pharma is — arguably — “over the social media hump.” Everyone now “wants to do it”. But how does pharma do it? How can companies successfully use social media to market their messages and their products? That’s the question addressed in Pharm Exec’s new episode of Pharma Faceoff, chaired by Barbara Ryan of Deutsche Bank. Read more »